Bin Essa, Noora;
Kaplar, Zoltan;
Balaji, Nikita;
Alduraibi, Alaa;
Bomanji, Jamshed;
Groves, Ashley M;
Lilburn, David ML;
... Fraioli, Francesco; + view all
(2023)
PET/CT in treatment response assessment in lung cancer. When should it be recommended?
Nuclear Medicine Communications
, 44
(12)
pp. 1059-1066.
10.1097/MNM.0000000000001757.
Preview |
Text
Fraioli_Treatment response_Final Manuscript_ZK_20.08.2023 (1) (1).pdf Download (320kB) | Preview |
Abstract
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Different treatment options are now possible both for surgical candidates and for those NSCLC patients deemed not suitable for surgery. Despite the treatments available, only a limited number of less advanced stages are potentially curable, with many patients suffering local recurrence or distant metastases. FDG-PET/CT is commonly used in many centers for post-treatment evaluation, follow-up, or surveillance; Nonetheless, there is no clear consensus regarding the indications in these cases. Based upon the results of a literature review and local expertise from a large lung cancer unit, we built clinical evidence-based recommendations for the use of FDG-PET/CT in response assessment. We found that in general this is not recommended earlier than 3 months from treatment; however, as described in detail the correct timing will also depend upon the type of treatment used. We also present a structured approach to assessing treatment changes when reporting FDG-PET/CT, using visual or quantitative approaches.
| Type: | Article |
|---|---|
| Title: | PET/CT in treatment response assessment in lung cancer. When should it be recommended? |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1097/MNM.0000000000001757 |
| Publisher version: | https://doi.org/10.1097/MNM.0000000000001757 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Department of Imaging |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10179969 |
Archive Staff Only
 |
View Item |
